NEW YORK – UK-based Hemogenyx Pharmaceuticals has inked a research agreement with the University of Pennsylvania for its CAR T-cell therapy for acute myeloid leukemia.
The agreement will enable the company to conduct key proof-of-concept studies for its HEMO-CAR-T product in AML. Saar Gill, co-director of the cell therapy and transplantation program at UPenn, will be principal investigator.
"This is a first and incredibly important step on a direct path to clinical trials for one of our leading product candidates," Hemogenyx CEO Vladislav Sandler said in a statement. "We are confident that this collaboration will dramatically accelerate the development of our CAR T product candidate."
Hemogenyx stated that it is focusing on developing its CAR T-cell therapy in AML because there is an unmet need for safe and effective treatments. Fewer than 30 percent of AML patients survive for five years and most receive chemotherapy.